132 related articles for article (PubMed ID: 16447136)
1. Tailoring the strategies to specific shortages: pneumococcal conjugate vaccine.
Peter G
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S138-40. PubMed ID: 16447136
[TBL] [Abstract][Full Text] [Related]
2. Who's calling the shots? Pediatricians' adherence to the 2001-2003 pneumococcal conjugate vaccine-shortage recommendations.
Broder KR; MacNeil A; Malone S; Schwartz B; Baughman AL; Murphy TV; Pickering LK; Moran JS
Pediatrics; 2005 Jun; 115(6):1479-87. PubMed ID: 15930207
[TBL] [Abstract][Full Text] [Related]
3. Pediatricians' adherence to pneumococcal conjugate vaccine shortage recommendations in 2 national shortages.
Fairbrother G; Broder K; Staat MA; Schwartz B; Heubi C; Hiratzka S; Walker FJ; Morrow AL
Pediatrics; 2007 Aug; 120(2):e401-9. PubMed ID: 17646354
[TBL] [Abstract][Full Text] [Related]
4. Temporary vaccine recommendations and provider compliance: a survey of pediatric practices during the 2003-2004 pneumococcal conjugate vaccine shortage.
Groom H; Bhatt A; Washington ML; Santoli J
Pediatrics; 2008 Oct; 122(4):e835-40. PubMed ID: 18829781
[TBL] [Abstract][Full Text] [Related]
5. Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey.
Smith PJ; Nuorti JP; Singleton JA; Zhao Z; Wolter KM
Pediatrics; 2007 Nov; 120(5):e1165-73. PubMed ID: 17974712
[TBL] [Abstract][Full Text] [Related]
6. Physician compliance with pneumococcal conjugate vaccine shortage recommendations in 2004.
Kolasa MS; Tannenbaum SM; Stevenson JM
J Public Health Manag Pract; 2007; 13(6):578-83. PubMed ID: 17984711
[TBL] [Abstract][Full Text] [Related]
7. [Present view of conjugated pneumococcus vaccines].
Prymula R
Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):98-102. PubMed ID: 17051470
[TBL] [Abstract][Full Text] [Related]
8. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
[TBL] [Abstract][Full Text] [Related]
9. Using registry data to evaluate the 2004 pneumococcal conjugate vaccine shortage.
Allred NJ; Stevenson JM; Kolasa M; Bartlett DL; Schieber R; Enger KS; Shefer A
Am J Prev Med; 2006 Apr; 30(4):347-50. PubMed ID: 16530623
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal conjugate vaccines. A review.
Galiza EP; Heath PT
Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
[TBL] [Abstract][Full Text] [Related]
11. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
13. Prevenar vaccination: review of the global data, 2006.
Center KJ
Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
[TBL] [Abstract][Full Text] [Related]
14. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar].
Reinert P; Dejos V; Clyti N; Abitbol V
Arch Pediatr; 2008 Mar; 15(3):263-70. PubMed ID: 18272353
[TBL] [Abstract][Full Text] [Related]
16. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
[TBL] [Abstract][Full Text] [Related]
17. Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts.
Nuorti JP; Martin SW; Smith PJ; Moran JS; Schwartz B
Am J Prev Med; 2008 Jan; 34(1):46-53. PubMed ID: 18083450
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
19. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Neuzil KM; Nahm MH; Whitney CG; Yu O; Nelson JC; Starkovich PT; Dunstan M; Carste B; Shay DK; Baggs J; Carlone GM
Vaccine; 2007 May; 25(20):4029-37. PubMed ID: 17391816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
